Yin, H., Liu, N
559 Administering small molecule ferroptosis inhibitors improves neurodegeneration in GPX4BIKO mice, indicating ferroptosis may play a crucial role in the pathology of AD
Previous research has been mixed and limited, he said
Translational research of accumulation-related toxicity biomarkers Clinical translation of candidate biomarkers directly linked to platinum accumulation should be prioritized for early prediction of long-term toxicities, including mitochondrial function markers (TFAM, TIMM23), cellular senescence marker p16 (Li et al
Peptide Research Trends 2026
If you see these patterns in any GLP-1 telehealth platform's marketing, they are the exact claims FDA has called misleading: Calling compounded semaglutide or tirzepatide a "generic" version of Ozempic or Wegovy - compounded drugs are not FDA-approved generics Implying FDA approved or reviewed the compounded product for safety, effectiveness, or quality - the FDA hasn't Claiming the pharmacy is "FDA-approved" or "FDA-licensed" - FDA registers facilities but does not "approve" or "license" compounding pharmacies in the way that phrase implies Branding compounded medication with the telehealth company's name in a way that suggests the telehealth company is the compounder - they're not Any messaging that implies the compounded product is "clinically proven" to perform the same as the FDA-approved branded drug This article avoids all of those patterns